Literature DB >> 16504458

Blue-dye intraoperative sentinel lymph node mapping in early non-small cell lung cancer.

W Rzyman1, O M Hagen, R Dziadziuszko, G Kobierska-Gulida, A Karmolinski, M I Lothe, W Paleczka, M Murawski, T Jastrzebski, A Kopacz, J Jassem, J Skokowski.   

Abstract

AIMS: The blue-dye staining method of sentinel lymph node identification in lung cancer patients has been scarcely reported. The study was designed to assess the sensitivity, accuracy and negative predictive value (NPV) of intraoperative sentinel lymph node mapping in patients with non-small cell lung cancer by means of staining with colloid or water solution of blue dye. PATIENTS AND METHODS: One hundred and ten patients with clinically confirmed NO non-small cell lung cancer were enrolled into prospective study of intraoperative sentinel node identification. Four quadrants of the peritumoral tissue were injected with 4 ml of blue dye. After complete lymphadenectomy, all resected lymph nodes were examined with conventional hematoxylin-eosine staining. All negative sentinel nodes were searched for metastatic deposits with both serial sections and immunohistochemistry for cytokeratines.
RESULTS: The blue-dye technique was characterized by unacceptably low sentinel node identification rate (IR) and low sensitivity (27% and 67% respectively). No significant differences were found in either the sensitivity or NPV among the colloid or water solutions of the blue dye applied. Although patent blue (colloid) was superior to water solution of methylene blue in identifying sentinel lymph node (identification rate 36% and 22% respectively) the sensitivity and NPV were lower (63% and 80% for patent blue and 75% and 92% for methylene blue respectively).
CONCLUSION: The blue-dye staining method of sentinel node identification in non-small cell lung cancer patients is inadequate and should not be recommended for clinical use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504458     DOI: 10.1016/j.ejso.2006.01.005

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

1.  A novel technique for tumor localization and targeted lymphatic mapping in early-stage lung cancer.

Authors:  Krista J Hachey; Christopher S Digesu; Katherine W Armstrong; Denis M Gilmore; Onkar V Khullar; Brian Whang; Hisashi Tsukada; Yolonda L Colson
Journal:  J Thorac Cardiovasc Surg       Date:  2017-02-10       Impact factor: 5.209

2.  Surgery for mediastinal lymph node and early stage lung cancer: individualized practice based on clinical database.

Authors:  Yi-Ting Yen; Yau-Lin Tseng
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 3.  Current innovations in sentinel lymph node mapping for the staging and treatment of resectable lung cancer.

Authors:  Krista J Hachey; Yolonda L Colson
Journal:  Semin Thorac Cardiovasc Surg       Date:  2014-09-16

Review 4.  From Diagnosis to Treatment: Clinical Applications of Nanotechnology in Thoracic Surgery.

Authors:  Christopher S Digesu; Sophie C Hofferberth; Mark W Grinstaff; Yolonda L Colson
Journal:  Thorac Surg Clin       Date:  2016-05       Impact factor: 1.750

5.  Video-rate fluorescence diffuse optical tomography for in vivo sentinel lymph node imaging.

Authors:  Metasebya Solomon; Brian R White; Ralph E Nothdruft; Walter Akers; Gail Sudlow; Adam T Eggebrecht; Samuel Achilefu; Joseph P Culver
Journal:  Biomed Opt Express       Date:  2011-11-08       Impact factor: 3.732

6.  Sentinel lymph node mapping in tumors of the pancreatic body: preliminary report.

Authors:  Adam Durczyński; Piotr Hogendorf; Dariusz Szymański; Piotr Grzelak; Janusz Strzelczyk
Journal:  Contemp Oncol (Pozn)       Date:  2012-07-06

7.  Long-term outcomes of sentinel node identification using indocyanine green in patients with lung cancer.

Authors:  Yukikiyo Kawakami; Kazuya Kondo; Naoya Kawakita; Hisashi Matsuoka; Hiroaki Toba; Hiromitsu Takizawa; Mitsuteru Yoshida; Akira Tangoku
Journal:  Thorac Cancer       Date:  2020-11-21       Impact factor: 3.223

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.